Portal de Periódicos da CAPES

Refractory cutaneous lupus erythematosus successfully treated with anifrolumab: a case series

2024; Wiley; Linguagem: Inglês

10.1111/ijd.17022

1365-4632

Daniel Martín‐Torregrosa, Miguel Mansilla‐Polo, Miguel Antonio Lasheras‐Pérez, Rafael Botella‐Estrada, Ignacio Torres‐Navarro,

Autoimmune Bullous Skin Diseases

International Journal of DermatologyVolume 63, Issue 3 p. 368-370 Clinical Correspondence Refractory cutaneous lupus erythematosus successfully treated with anifrolumab: a case series Daniel Martín-Torregrosa, Corresponding Author Daniel Martín-Torregrosa [email protected] orcid.org/0009-0008-7918-4733 Hospital Universitario y Politécnico La Fe, Valencia, Spain Instituto de Investigación Sanitaria La Fe, IIS La Fe, Valencia, SpainSearch for more papers by this authorMiguel Mansilla-Polo, Miguel Mansilla-Polo orcid.org/0000-0001-6730-6723 Hospital Universitario y Politécnico La Fe, Valencia, Spain Instituto de Investigación Sanitaria La Fe, IIS La Fe, Valencia, SpainSearch for more papers by this authorMiguel Antonio Lasheras-Pérez, Miguel Antonio Lasheras-Pérez orcid.org/0000-0001-7429-9592 Hospital Universitario y Politécnico La Fe, Valencia, Spain Instituto de Investigación Sanitaria La Fe, IIS La Fe, Valencia, SpainSearch for more papers by this authorRafael Botella-Estrada, Rafael Botella-Estrada Hospital Universitario y Politécnico La Fe, Valencia, Spain Instituto de Investigación Sanitaria La Fe, IIS La Fe, Valencia, SpainSearch for more papers by this authorIgnacio Torres-Navarro, Ignacio Torres-Navarro orcid.org/0000-0002-5448-5360 Hospital Universitario y Politécnico La Fe, Valencia, Spain Instituto de Investigación Sanitaria La Fe, IIS La Fe, Valencia, SpainSearch for more papers by this author Daniel Martín-Torregrosa, Corresponding Author Daniel Martín-Torregrosa [email protected] orcid.org/0009-0008-7918-4733 Hospital Universitario y Politécnico La Fe, Valencia, Spain Instituto de Investigación Sanitaria La Fe, IIS La Fe, Valencia, SpainSearch for more papers by this authorMiguel Mansilla-Polo, Miguel Mansilla-Polo orcid.org/0000-0001-6730-6723 Hospital Universitario y Politécnico La Fe, Valencia, Spain Instituto de Investigación Sanitaria La Fe, IIS La Fe, Valencia, SpainSearch for more papers by this authorMiguel Antonio Lasheras-Pérez, Miguel Antonio Lasheras-Pérez orcid.org/0000-0001-7429-9592 Hospital Universitario y Politécnico La Fe, Valencia, Spain Instituto de Investigación Sanitaria La Fe, IIS La Fe, Valencia, SpainSearch for more papers by this authorRafael Botella-Estrada, Rafael Botella-Estrada Hospital Universitario y Politécnico La Fe, Valencia, Spain Instituto de Investigación Sanitaria La Fe, IIS La Fe, Valencia, SpainSearch for more papers by this authorIgnacio Torres-Navarro, Ignacio Torres-Navarro orcid.org/0000-0002-5448-5360 Hospital Universitario y Politécnico La Fe, Valencia, Spain Instituto de Investigación Sanitaria La Fe, IIS La Fe, Valencia, SpainSearch for more papers by this author First published: 10 January 2024 https://doi.org/10.1111/ijd.17022 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020; 382(3): 211–221. 10.1056/NEJMoa1912196 CASPubMedWeb of Science®Google Scholar 2Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019; 1(4): e208–e219. 10.1016/S2665-9913(19)30076-1 PubMedGoogle Scholar 3Chasset F, Jaume L, Mathian A, Abisror N, Dutheil A, Barbaud A, et al. Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus. J Am Acad Dermatol. 2023; 89(1): 171–173. 10.1016/j.jaad.2023.02.044 CASPubMedWeb of Science®Google Scholar 4Blum FR, Sampath AJ, Foulke GT. Anifrolumab for treatment of refractory cutaneous lupus erythematosus. Clin Exp Dermatol. 2022; 47(11): 1998–2001. 10.1111/ced.15335 PubMedWeb of Science®Google Scholar 5Frumholtz L, Bouaziz JD, Battistella M, Hadjadj J, Chocron R, Bengoufa D, et al. Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak. Br J Dermatol. 2021; 185(6): 1176–1185. 10.1111/bjd.20707 CASPubMedWeb of Science®Google Scholar Volume63, Issue3March 2024Pages 368-370 ReferencesRelatedInformation